Related Experiment Video

Updated: Mar 5, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K

Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg

Adélaïde Durand1, Maithé Tauber1, Bharat Patel2

  • 1Unité de Pédiatrie, Endocrinologie, Obésité, Maladies Osseuses, Génétique et Gynécologie Médicale, Hôpital des Enfants, CHU de Toulouse, Toulouse, France.

Hormone Research in Paediatrics
|March 24, 2017
PubMed

Insights

Triptorelin 11.25 mg effectively suppresses luteinizing hormone (LH) and other hormones in children with central precocious puberty (CPP). This 3-month formulation demonstrates efficacy in managing CPP progression.

Area of Science:

  • Pediatric Endocrinology
  • Reproductive Medicine
  • Pharmacology

Background:

  • Central precocious puberty (CPP) involves early onset of puberty due to premature activation of the hypothalamic-pituitary-gonadal axis.
  • Effective management of CPP is crucial to prevent adverse outcomes such as short stature and psychosocial issues.
  • Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, is a standard treatment for CPP.

Purpose of the Study:

  • To evaluate the efficacy of the triptorelin 11.25 mg 3-month prolonged-release formulation in treating central precocious puberty (CPP).
  • To assess the suppression of key hormonal markers indicative of pubertal progression.

Main Methods:

  • A meta-analysis was conducted, including all available clinical studies of triptorelin 11.25 mg.
  • The primary outcome measured was the proportion of children achieving suppressed luteinizing hormone (LH) response (peak LH ≤3 IU/L) 3 months post-injection.
  • Secondary outcomes included hormonal suppression at 6 months and suppression of follicle-stimulating hormone (FSH), estradiol, and testosterone at 3 months.

Main Results:

  • The study included 153 children (13 boys, 140 girls).
  • A significant proportion of children achieved suppressed LH response: 87.6% at 3 months and 92.8% at 6 months.
  • At 3 months, suppressed FSH, estradiol, and testosterone levels were observed in 86.7%, 97.1%, and 72.7% of children, respectively.

Conclusions:

  • Triptorelin 11.25 mg administered every 3 months is an efficacious treatment for central precocious puberty.
  • The formulation effectively suppresses LH peak and other gonadal hormones.
  • This treatment aids in slowing the progression of CPP in pediatric patients.
Abstract

Keywords:
Central precocious pubertyEfficacyGonadotrophin-releasing hormone analogueMeta-analysisTriptorelin 3-month formulation

More Related Videos

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

12.0K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

2.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
303
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
398
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
503
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
352
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
235